A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma
M23-001
Phase 1 other active
Quick answer
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma for Relapsed or Refractory Multiple Myeloma (R/R MM) is a Phase 1 program (other) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Relapsed or Refractory Multiple Myeloma (R/R MM)
- Phase
- Phase 1
- Modality
- other
- Status
- active